Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial


Sanofi SA SNY and Regeneron Pharmaceuticals Inc REGN have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU).

  • The trial included CSU patients who don't respond to biologic treatment, Novartis AG NVSRoche Holdings AG's RHHBY Xolair (omalizumab). 
  • CSU is a severe form of hives, causing severe itching and swelling.
  • In the study, dupilumab couldn't significantly improve symptoms in Xolair-refractory patients.
  • The trial will be stopped for futility, although the antibody did show "numeric improvements" on itching and hive symptoms.
  • Related: Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis.
  • The previously reported Phase 3 trial, which evaluated CSU patients who were biologic-naïve, met its primary and all key secondary endpoints at 24 weeks.
  • Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives compared to antihistamines alone.
  • The companies are evaluating the next steps.
  • Price Action: SNY shares are trading higher by 0.49% at $53.13 during the premarket session on the last check Friday, while REGN stock closed at $626.72 on Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!